ClinicalTrials.gg
RecruitingNCT07459426Updated Oct 13, 2026

Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)

An observational study in Hepatitis B, Chronic, sponsored by Yaşar Bayındır, MD. Recruiting at 10 sites in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Yaşar Bayındır, MD · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 13, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
700
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Hepatitis B, Chronic with a site in Turkey — 1 open to participants now, 1 under way, none of them phase 3. Hepatitis B, Chronic · Turkey.

Started
2026
with 1 other
Observational
6 of 31
1 open now
Registered
30th of 31
by date
Lead sponsor
2 of 31
Yaşar Bayındır, MD

Among the 31 studies in Hepatitis B, Chronic with a site in Turkey, this one is one of 2 that started in 2026, is one of 6 observational ones, and was the 30th registered.

Hepatitis B, Chronic

899 studies on the registry are indexed under Hepatitis B, Chronic; 154 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

1 of the 31 studies in Hepatitis B, Chronic with a site in Turkey is open now.

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Hepatitis B, Chronic with a site in Turkey, or all of them as a file.
02

Study summary

Chronic hepatitis B is a long-term viral infection that affects millions of people worldwide. Patients usually require lifelong antiviral treatment to control the virus and prevent liver damage.

Some older antiviral medications, such as lamivudine, can lead to the development of viral resistance. This means the virus changes in a way that makes certain treatments less effective. Even though newer drugs like entecavir are stronger and more resistant to these changes, previous exposure to lamivudine may increase the risk of developing additional resistance mutations.

By analyzing viral genetic material from blood samples using advanced sequencing technology, this research will help improve understanding of antiviral resistance patterns in patients with chronic hepatitis B in Turkey and may support better treatment decisions in the future.

Read the detailed description

Hypothesis

  1. Entecavir resistance-associated mutations are detectable in both naïve and lamivudine-experienced patients.
  2. Prevalence is higher in lamivudine-experienced patients compared to treatment-naïve patients.
  3. Longer lamivudine exposure and higher HBV-DNA are associated with resistance.
  4. Nanopore sequencing detects minor resistance variants not captured by conventional methods.

Sample size: 700 estimated participants

Pre-existing lamivudine-induced resistance mutations create a genetic background that facilitates the emergence of secondary entecavir resistance mutations, even in patients currently receiving tenofovir-based therapy.

Investigators further hypothesize that peripheral blood-derived cccDNA sequencing can serve as a minimally invasive method to characterize transmitted and acquired resistance mutation profiles in chronic HBV infection.

Clinical Significance Chronic hepatitis B management relies on long-term antiviral therapy, and resistance-associated mutations significantly influence treatment success and future therapeutic strategies.

Although entecavir has a high genetic barrier, prior lamivudine exposure may predispose patients to secondary resistance mutations, potentially compromising antiviral efficacy. However, the prevalence and distribution of such mutations in the Turkish HBV population remain insufficiently characterized

This study will provide:

  • National-level data on entecavir resistance-associated mutations
  • Comparative analysis between treatment-naïve and lamivudine-experienced patients
  • Insight into the clinical relevance of minor resistance variants detected by long-read sequencing Peripheral blood-derived cccDNA sequencing may represent a minimally invasive resistance monitoring tool.

The findings may contribute to optimizing antiviral selection strategies, guiding individualized treatment decisions, and informing national hepatitis B management policies.

This study will provide national-level data on entecavir resistance mutations in Turkey.

It may support individualized antiviral selection and contribute to national HBV management strategies.

03

Conditions studied

  • Hepatitis B, Chronic

Browse trials for

Keywords

  • Chronic hepatitis B
  • Lamivudine
  • Entecavir
  • Antiviral resistance
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult (≥18 years) HBsAg-positive patients with a documented history of lamivudine therapy for ≥6 months who were subsequently switched to tenofovir-based therapy (ADV, TDF, or TAF) and have not received entecavir or telbivudine.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • positive
  • Group 1: Either treatment-naïve participants with HBV DNA>2000 IU/ml
  • Group 2: Prior lamivudine therapy ≥6 months with switch to ADVor TDF or TAF
  • Ability to provide

Exclusion criteria

Exclusion Criteria:

  • Prior entecavir exposure
  • Prior telbivudine exposure
  • Age \<18 years
  • Inability to provide Note: Previous adefovir or (pegylated) interferon use is not an exclusion criterion.

Patients with insufficient sample volume or inadequate DNA quality for sequencing will be excluded from final analysis.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
700 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Treatment-Naïve Chronic HBV Patients

    Adult (≥18 years) HBsAg-positive patients with HBV-DNA \>2,000 IU/mL who have not received prior nucleos(t)ide analogue therapy.

    Diagnostic Test: Viral genetic material from blood samples using advanced sequencing technology

  • Lamivudine-Experienced Chronic HBV Patients

    Adult (≥18 years) HBsAg-positive patients with a documented history of lamivudine therapy for ≥6 months who were subsequently switched to tenofovir-based therapy (ADV, TDF, or TAF) and have not received entecavir or telbivudine.

    Diagnostic Test: Viral genetic material from blood samples using advanced sequencing technology

Interventions

  • Diagnostic testViral genetic material from blood samples using advanced sequencing technology

    No intervention

06

What researchers measure

Primary outcomes

  1. Prevalence of entecavir resistance-associated mutations in the HBV polymerase/RT region detected by Oxford Nanopore sequencing.

    Detection of entecavir resistance-associated mutations (T184, S202, M250), with or without lamivudine resistance background mutations (L180M, M204V/I), in the HBV polymerase/RT region by Oxford Nanopore sequencing of peripheral blood-derived cccDNA. Mutations will be reported if detected at an allele frequency ≥5%.

    Time frame: March 15th, 2026-March 15th, 2027

Secondary outcomes

  1. Comparison of mutations between two groups.

    Comparison of mutation frequency between treatment-naïve and lamivudine-experienced patients. Comparison of mutation frequency between treatment-naïve and lamivudine-experienced patients. Comparison of mutation frequency between treatment-naïve and lamivudine-experienced patients.

    Time frame: March 15th, 2026-March 15th, 2027

  2. Association between HBV-DNA level and resistance-associated mutation presence.

    Association between HBV-DNA level and resistance-associated mutation presence in all groups.

    Time frame: March 15th, 2026-March 15th, 2027

  3. Duration of lamivudine exposure and secondary mutations.

    Association between duration of lamivudine exposure and secondary mutations.

    Time frame: March 15th, 2026-March 15th, 2027

  4. Classical lamivudine resistance mutations and their co-occurrence with ETV resistance mutations.

    Detection of classical lamivudine resistance mutations (M204V/I, L180M) and their co-occurrence with ETV resistance mutations.

    Time frame: March 15th, 2026-March 15th, 2027

07

Study locations

2 of 10 sites recruiting
  • Cukurova University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
    Adana, Turkey (Türkiye)
    Not yet recruiting
    • Yesim Tasova, MD, Prof. · Contactytasova@gmail.com · +905353088511
    • Yesim Tasova, MD, Prof. · Principal investigator
  • Gazi University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
    Ankara, Turkey (Türkiye)
    Not yet recruiting
    • Yesim Yildiz, MD, Assoc. Prof. · Contactyesim_2323_1989@hotmail.com · +905556109871
    • Yesim Yildiz, MD, Assoc. Prof. · Principal investigator
  • Health Sciences University Hamidiye Faculty of Medicine
    Ankara, Turkey (Türkiye)
    Not yet recruiting
    • Funda Simsek, MD, Prof. · Contactfundasimsek67@gmail.com · +905325620953
    • Funda Simsek, MD, Assoc. Prof. · Principal investigator
  • Akdeniz University, Faculty of Medicine
    Antalya, Turkey (Türkiye)
    Not yet recruiting
    • Dilara Inan, MD, Prof. · Contactinan@akdeniz.edu.tr · +905323706725
    • Dilara Inan, MD, Prof. · Principal investigator
  • Dicle University, Faculty of Medicine
    Diyarbakır, Turkey (Türkiye)
    Recruiting
    • Mustafa Kemal Celen, MD, Prof. · Contactmkcelen@hotmail.com · +905336207022
    • Cigdem Mermutluoglu, MD., Assoc. Prof. · Contactcigdemmermut@gmail.com · +905052252700
    • Mustafa Kemal Celen, MD, Prof. · Principal investigator
    • Cigdem Mermutluoglu, MD, Assoc. Prof. · Sub investigator
  • Gaziantep University
    Gaziantep, Turkey (Türkiye)
    Recruiting
    • Ayse Ozlem Mete, MD · Contactayseozlem_ornek@hotmail.com · +905064883309
    • Ilkay Karaoglan, MD, Prof. · Contactilkayn.can@gmail.com · +905359266763
    • Ayse Ozlem Mete, MD, Assoc. Prof. · Principal investigator
    • Ilkay Karaoglan, MD, Prof. · Sub investigator
    • Irem Ece Ersari, Research Assistant Physician · Sub investigator
  • Ege University, Faculty of Medicine
    Izmir, Turkey (Türkiye)
    Not yet recruiting
    • Tansu Yamazhan, MD, Prof. · Contacttansuyamazhan@gmail.com · 905325060470
    • Tansu Yamazhan, MD, Prof. · Principal investigator
  • Kocaeli University, Faculty of Medicine
    Kocaeli, Turkey (Türkiye)
    Not yet recruiting
    • Sila Akhan, MD, Prof. · Contactsila.akhan@kocaeli.edu.tr · +905322666535
    • Sila Akha, MD, Prof. · Principal investigator
    • Melih Esgin, Research Assistant Physician · Sub investigator
  • İnönü University, Faculty of Medicine, Department of Clinical Microbiology
    Malatya, Turkey (Türkiye)
    Not yet recruiting
    • Baris Otlu, PhD, Prof. · Contactbotlu@yahoo.com · +905333710780
    • Baris Otlu, PhD, Prof. · Principal investigator
    • Elif Seren Tanriverdi, MD., Asist. Prof. · Sub investigator
  • Samsun Ondokuz Mayıs University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology
    Samsun, Turkey (Türkiye)
    Not yet recruiting
    • Ozgur Gunal, MD, Prof. · Contactozgurgop@yahoo.com · +905052543167
    • Ozgur Gunal, MD, Prof. · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Prevalence of entecavir resistance-associated mutations in the HBV polymerase/RT region detected by Oxford Nanopore sequencing.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Mar 2026 (actual). Primary completion is estimated for Dec 2026, 9 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: primary completion Sep 2026 → Dec 2026 and completion Mar 2027 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 28, 2026
First posted
Mar 9, 2026
StartActual
Mar 15, 2026
Primary completionEst.
Dec 15, 2026was Sep 2026
CompletionEst.
Sep 15, 2027was Mar 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
9 sites added. Gaziantep University is now Recruiting
Show 9 added (9 Turkey (Türkiye))
  • Cukurova University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology · Adana, Turkey (Türkiye)
  • Gazi University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology · Ankara, Turkey (Türkiye)
  • Health Sciences University Hamidiye Faculty of Medicine · Ankara, Turkey (Türkiye)
  • Akdeniz University, Faculty of Medicine · Antalya, Turkey (Türkiye)
  • Dicle University, Faculty of Medicine · Diyarbakır, Turkey (Türkiye)
  • Ege University, Faculty of Medicine · Izmir, Turkey (Türkiye)
  • Kocaeli University, Faculty of Medicine · Kocaeli, Turkey (Türkiye)
  • İnönü University, Faculty of Medicine, Department of Clinical Microbiology · Malatya, Turkey (Türkiye)
  • Samsun Ondokuz Mayıs University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology · Samsun, Turkey (Türkiye)
Oct 13, 2026
Primary completion
Sep 15, 2026→Dec 15, 2026
Oct 13, 2026
Study completion
Mar 15, 2027→Sep 15, 2027
Oct 13, 2026
Contact
Study contact now listed: added y•••@guven.com.tr · •••9909. See the current contact
Oct 13, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Gaziantep University · Gaziantep, Turkey (Türkiye)Contact a•••@hotmail.com · •••3309→a•••@hotmail.com · •••3309Contact added i•••@gmail.com · •••6763Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    9 sites added. Gaziantep University is now Recruiting
    Show 9 added (9 Turkey (Türkiye))
    • Cukurova University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology · Adana, Turkey (Türkiye)
    • Gazi University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology · Ankara, Turkey (Türkiye)
    • Health Sciences University Hamidiye Faculty of Medicine · Ankara, Turkey (Türkiye)
    • Akdeniz University, Faculty of Medicine · Antalya, Turkey (Türkiye)
    • Dicle University, Faculty of Medicine · Diyarbakır, Turkey (Türkiye)
    • Ege University, Faculty of Medicine · Izmir, Turkey (Türkiye)
    • Kocaeli University, Faculty of Medicine · Kocaeli, Turkey (Türkiye)
    • İnönü University, Faculty of Medicine, Department of Clinical Microbiology · Malatya, Turkey (Türkiye)
    • Samsun Ondokuz Mayıs University, Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology · Samsun, Turkey (Türkiye)
    Primary completion Sep 15, 2026→Dec 15, 2026
    Study completion Mar 15, 2027→Sep 15, 2027
    Contact Study contact now listed: added y•••@guven.com.tr · •••9909. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Gaziantep University · Gaziantep, Turkey (Türkiye)Contact a•••@hotmail.com · •••3309→a•••@hotmail.com · •••3309Contact added i•••@gmail.com · •••6763Contact added (no phone or email listed)Contact added (no phone or email listed)Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07459426
Lead sponsor
Yaşar Bayındır, MD
Collaborators
SOUTHEAST NEUROLOGY AND INFECTIOUS DISEASES SOCIETY
Responsible party
Yaşar Bayındır, MD (Chief Physican, Guven Health Group) — Sponsor-investigator
First posted
Mar 9, 2026
Start date
Mar 15, 2026
Primary completion
Dec 15, 2026 (estimated)
Completion
Sep 15, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Yaşar Bayındır, MD, Prof.
Contact
yasar.bayindir@guven.com.tr
+905323659909

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion